María Victoria Castelli,Marcos Gabriel Derita,Silvia Noelí López
María Victoria Castelli
Superficial infections involving the skin and mucosa are the most common fungal disease in humans. Fungi can also produce invasive infections (IFI), which are increasing in incidence among the growing population of immunocompromised patient...
Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2) [0.03%]
具有吡啶甲腈基团的新 Diaryltriazine 类HIV-1 RT抑制剂：关于WO2016059647（A2）的专利评估
Boshi Huang,Zhongxia Zhou,Dongwei Kang et al.
Boshi Huang et al.
Diaryltriazine derivatives, which are structurally related to diarylpyrimidines, are a representative class of HIV-1 reverse transcriptase inhibitors with remarkable antiviral activities against wild-type and several mutant strains of HIV-1...
Recent advances in therapeutics and drug delivery for the treatment of inner ear diseases: a patent review (2011-2015) [0.03%]
内耳疾病治疗的药物及给药方式的新进展(2011-2015):基于专利的综述
Kim Nguyen,Judith S Kempfle,David H Jung et al.
Kim Nguyen et al.
Inner ear disorders such as hearing loss, tinnitus, and Ménière's disease significantly impact the quality of life of affected individuals. Treatment of such disorders is an ongoing challenge. Current clinical approaches relieve symptoms ...
RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345 [0.03%]
维泰制药VTP-43742的潜在备用药物RORγt抑制剂：WO2016061160和US20160122345专利分析评价
Christian Gege
Christian Gege
Retinoic acid receptor-related orphan nuclear receptor gamma t (RORγt or RORc2) is a key transcription factor for the differentiation of naïve proinflammatory CD4+ T cells and the production of T helper-17 (TH17) cells. Inhibiting RORγt ...
An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015) [0.03%]
尿酸酶抑制剂治疗高尿酸血症和痛风的专利分析(2011-2015)
Ritu Ojha,Jagjeet Singh,Anu Ojha et al.
Ritu Ojha et al.
Xanthine oxidase (XO) is a versatile molybdoflavoprotein, widely distributed, occurring in milk, kidney, lung, heart, and vascular endothelium. Catalysis by XO to produce uric acid and reactive oxygen species leads to many diseases. Anti hy...
Treatments and compositions targeting α-synuclein: a patent review (2010-2016) [0.03%]
针对α-突触核蛋白的治疗和组合物：2010-2016年专利回顾
Henryk Jęśko,Anna M Lenkiewicz,Agata Adamczyk
Henryk Jęśko
Abnormal deposition of α-synuclein (ASN) is a hallmark and possible central mechanism of Parkinson's disease and other synucleinopathies. Their therapy is currently hampered by the lack of early, screening-compatible diagnostic methods and...
PARP inhibitors as antitumor agents: a patent update (2013-2015) [0.03%]
PARP抑制剂作为抗肿瘤制剂的专利更新（2013-2015）
Zigao Yuan,Jiwei Chen,Wenlu Li et al.
Zigao Yuan et al.
PARP inhibitors have been extensively explored as antitumor agents and have shown potent efficacy both in vitro and in vivo. They can be used in monotherapy under the synthetic lethality concept or in combination with radiotherapy or chemot...
Trends in therapeutic drug conjugates for bacterial diseases: a patent review [0.03%]
抗菌病治疗药偶联物的发展趋势：专利回顾
Pedro M S D Cal,Maria J Matos,Gonçalo J L Bernardes
Pedro M S D Cal
Drug conjugates are trend topics in Chemical Biology. These entities are an emerging class of highly potent biopharmaceutical drugs, best known in the field of oncology, that have been also designed as a targeted therapy/diagnosis for the t...
Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015) [0.03%]
论甘露聚糖肽注射液免疫调节作用的机制研究进展
Valle Palomo,Ana Martinez
Valle Palomo
Glycogen synthase kinase (GSK-3) is a serine/threonine kinase that phosphorylates more than one hundred different sequences within proteins in a variety of different pathways. It is a key component of a remarkably large number of cellular p...
Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections [0.03%]
利用酶催化氨基酸剥夺作为癌症和病毒感染的靶向疗法
H S Fernandes,C S Silva Teixeira,P A Fernandes et al.
H S Fernandes et al.
Amino acid depletion in the blood serum is currently being exploited and explored for therapies in tumors or viral infections that are auxotrophic for a certain amino acid or have a metabolic defect and cannot produce it. The success of the...